Search results
4 days ago · Get the latest information on Moderna's stock price, news, financials, statistics, forecast, dividends and profile. See how Moderna's products, such as COVID-19 and RSV vaccines, are performing in the market and read the latest news and analysis.
- Moderna, Inc. (MRNA) Stock Forecast & Price Targets - Stock Analysis
Stock Price Forecast. The 15 analysts with 12-month price...
- Moderna, Inc. (MRNA) Stock Forecast & Price Targets - Stock Analysis
4 days ago · A high-level overview of Moderna, Inc. (MRNA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
3 days ago · Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%).
3 days ago · 18 brokerages have issued twelve-month price targets for Moderna's stock. Their MRNA share price targets range from $60.00 to $231.00. On average, they predict the company's share price to reach $134.02 in the next year. This suggests a possible upside of 15.6% from the stock's current price.
3 days ago · Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
4 days ago · Stock Price Forecast. The 15 analysts with 12-month price forecasts for Moderna stock have an average target of 139.8, with a low estimate of 86 and a high estimate of 231. The average target predicts an increase of 19.42% from the current stock price of 117.07.
5 days ago · Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%).
